Go Pro

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:RXII

RXi Pharmaceuticals (RXII) Stock Price, News & Analysis

RXi Pharmaceuticals logo

About RXi Pharmaceuticals Stock (NASDAQ:RXII)

Key Stats

Today's Range
$1.25
$1.30
50-Day Range
$0.36
$0.50
52-Week Range
$0.31
$7.70
Volume
139,747 shs
Average Volume
1.73 million shs
Market Capitalization
$5.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics that addresses unmet medical needs. Its clinical product candidate includes RXI-109, an RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.

Receive RXII Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RXi Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RXII Stock News Headlines

Rex International Holding Ltd (RXI.SG)
Galena's Breast Cancer Vaccine Doomed to Fail
Earth's biggest energy source: near Grand Canyon
The largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - and much of it sits beneath the desert near the Grand Canyon. A drilling crew just hit the DOE's 2035 targets twelve years early, with costs down 50% in 18 months. Google signed on, Gates invested, and the Pentagon made it a priority. One company has been quietly building this infrastructure for sixty years.tc pixel
Q4 2022 Catalyst Pharmaceuticals Inc Earnings Call
iShares Global Consumer Discretionary ETF (RXI)
See More Headlines

RXII Stock Analysis - Frequently Asked Questions

RXi Pharmaceuticals Co. (NASDAQ:RXII) posted its earnings results on Tuesday, August, 14th. The biotechnology company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.16. The biotechnology company had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.02 million. RXi Pharmaceuticals had a negative net margin of 4,990.20% and a negative trailing twelve-month return on equity of 412.15%.

RXi Pharmaceuticals shares reverse split on Monday, January 8th 2018.The 1-10 reverse split was announced on Friday, January 5th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 5th 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that RXi Pharmaceuticals investors own include Micron Technology (MU), Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Protalix BioTherapeutics (PLX) and Anavex Life Sciences (AVXL).

Company Calendar

Last Earnings
8/14/2018
Today
9/12/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:RXII
CIK
1533040
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($4.20)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$12.45 million
Net Margins
-4,990.20%
Pretax Margin
N/A
Return on Equity
-412.15%
Return on Assets
-179.54%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.77
Quick Ratio
1.77

Sales & Book Value

Annual Sales
$10 thousand
Price / Sales
569.40
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.77 per share
Price / Book
1.69

Miscellaneous

Outstanding Shares
4,380,000
Free Float
N/A
Market Cap
$5.69 million
Optionable
Not Optionable
Beta
2.07
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:RXII) was last updated on 9/12/2026 by MarketBeat.com Staff.
From Our Partners